Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 9/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 8/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 8/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 8/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 8/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 8/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 2/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Niguldipine SCHEMBL245992 | 1.00 | ADRA1A (1.00) | ADRA1AADRA2AADRA2BADRA2CADRA1D | |
| Dexniguldipine SCHEMBL29615752 | 1.00 | ADRA1A (1.00) | ADRA1AADRA2AADRA2BADRA2CADRA1D | |
| Dexniguldipine SCHEMBL724137 | 1.00 | ADRA1A (1.00) | ADRA1AADRA2AADRA2BADRA2CADRA1D | |
| Niguldipine SCHEMBL29385244 | 1.00 | ADRA1A (1.00) | ADRA1AADRA2AADRA2BADRA2CADRA1D | |
| Niguldipine SCHEMBL29386264 | 1.00 | ADRA1A (1.00) | ADRA1AADRA2AADRA2BADRA2CADRA1D | |
| Niguldipine SCHEMBL3869443 | 0.99 | ADRA1A (0.98) | ADRA1AADRA2AADRA2BADRA2CADRA1D | |
| Niguldipine SCHEMBL9001404 | 0.99 | ADRA1A (1.00) | ADRA1AADRA2AADRA2BADRA2CADRA1D | |
| Niguldipine SCHEMBL467245 | 0.99 | ADRA1A (1.00) | ADRA1AADRA2AADRA2BADRA2CADRA1D | |
| Dexniguldipine SCHEMBL1228966 | 0.99 | ADRA1A (1.00) | ADRA1AADRA2AADRA2BADRA2CADRA1D | |
| SCHEMBL9386117 | 0.98 | ADRA1A (0.95) | ADRA1AADRA2AADRA2BADRA2CADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1967 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025229029-A1 | CONJUGATE OF A SENOTHERAPEUTIC MOIETY AND A LIPID-TARGETING MOIETY | GORGOULIS VASSILIS G (GR) | 2025-11-06 | — | — | WO | claimed |
| US-20250213647-A1 | CHEMOKINE RECEPTORS AND ALPHA1 ADRENERGIC RECEPTORS/VASOPRESSIN RECEPTORS 1A HETEROMERS AS DRUG TARGETS FOR DISEASE | UNIVERSITY OF SOUTH FLORIDA | 2025-07-03 | — | — | US | claimed |
| US-20250186415-A1 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT | 2025-06-12 | — | — | US | claimed |
| WO-2025034510-A1 | ADRENERGIC ANTAGONISTS FOR USE IN A METHOD FOR TREATING CEREBRAL EDEMA OR A BRAIN INJURY | UNIVERSITY OF ROCHESTER (US) | 2025-02-13 | — | — | WO | claimed |
| EP-4489858-A1 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | Harrow IP, LLC (US) | 2025-01-15 | — | — | EP | claimed |
| US-20230330188-A1 | PHARMACEUTICAL COMBINATION FOR USE IN THE TREATMENT AND/OR PREVENTION OF DIABETES | INSPHERO AG (CH) | 2023-10-19 | — | — | US | claimed |
| WO-2023192319-A1 | CHEMOKINE RECEPTORS AND ALPHA1 ADRENERGIC RECEPTORS/VASOPRESSIN RECEPTORS 1A HETEROMERS AS DRUG TARGETS FOR DISEASE | UNIVERSITY OF SOUTH FLORIDA (US) | 2023-10-05 | — | — | WO | claimed |
| WO-2023172240-A1 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | HARROW IP, LLC (US) | 2023-09-14 | — | — | WO | claimed |
| EP-4225296-A1 | PHARMACEUTICAL COMBINATION FOR USE IN THE TREATMENT AND/OR PREVENTION OF DIABETES | Insphero AG (CH) | 2023-08-16 | — | — | EP | claimed |
| US-20220387408-A1 | USE OF MAST CELL STABILIZER FOR THE TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION | INST NAT SANTE RECH MED (FR) | 2022-12-08 | — | — | US | claimed |
| EP-1059912-A2 | USE OF A COMPOUND INHIBITING THE ACTIVITY OF A SODIUM CHANNEL AND A CALCIUM CHANNEL IN A COMPOSITION FOR TOPICAL USE | L'OREAL (FR) | 2000-12-20 | — | — | EP | claimed |
| WO-2000012075-A1 | NITROSATED AND NITROSYLATED ALPHA-ADRENERGIC RECEPTOR ANTAGONISTS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2000-03-09 | — | — | WO | claimed |
| WO-2000002543-A2 | ANTIHYPERSENSITIVE COMBINATION OF VALSARTAN AND CALCIUM CHANNEL BLOCKER | NOVARTIS AG (CH) | 2000-01-20 | — | — | WO | claimed |
| WO-1999044579-A2 | USE OF A COMPOUND INHIBITING THE ACTIVITY OF A SODIUM CHANNEL AND A CALCIUM CHANNEL IN A COMPOSITION FOR TOPICAL USE | L'OREAL (FR) | 1999-09-10 | — | — | WO | claimed |
| WO-1997038693-A1 | CALCIUM CHANNEL BLOCKERS AS HUMAN CONJUNCTIVAL MAST CELL DEGRANULATION INHIBITORS FOR TREATING OCULAR ALLERGIC CONDITIONS | ALCON LABORATORIES, INC. (US) | 1997-10-23 | — | — | WO | claimed |
| EP-0176956-B1 | Diaryl derivatives | BYK GULDEN LOMBERG CHEM FAB (DE) | 1994-06-15 | — | — | EP | claimed |
| EP-0584250-A4 | — | — | 1994-03-30 | — | — | EP | claimed |
| EP-0584250-A1 | NOVEL COMPOSITION OF ANGIOTENSIN-II RECEPTOR ANTAGONISTS AND CALCIUM CHANNEL BLOCKERS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1994-03-02 | — | — | EP | claimed |
| WO-1992020342-A1 | NOVEL COMPOSITION OF ANGIOTENSIN-II RECEPTOR ANTAGONISTS AND CALCIUM CHANNEL BLOCKERS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-11-26 | — | — | WO | claimed |
| US-4707486-A | Diaryl piperidine containing esters of 1,4-dihydropyridines and coronary therapeutic use | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1987-11-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330188-A1 | PHARMACEUTICAL COMBINATION FOR USE IN THE TREATMENT AND/OR PREVENTION OF DIABETES | IAPP, SLC5A2, GLP1R | ADRA1A 508/4885ADRA2A 351/4885ADRA2B 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.